The main near term catalysts are the LCD and anything related to 2RT. Obviously iTrack Advance sales updates will be great, but they won't move the price until we can get confirmation of continued reimbursement. For the LCD, I already have a stash of cash set aside to pour into this post-positive news. I personally will be willing to pay anything under 30c on the morning of the LCD news if all goes well on that front. With guaranteed future coverage, this will easily be a 50c+ stock (though it'll be up to the market to agree with that assessment). If 2RT secures a major partnership, then there is no reason to even worry about iTrack Advance as that'll be a major rerate catalyst
Boring right now but I'd say that's a good thing. The market is waiting, buy side stacked + thin sell side is highly conducive to supporting a strong rerate when the news comes.
Big weekend of news. ESCRS this weekend and then Morgan Stanley Health Care Conference start of next week.
- Forums
- ASX - By Stock
- EYE
- Nova Eye Medical (EYE) Discussion
Nova Eye Medical (EYE) Discussion, page-1152
-
-
- There are more pages in this discussion • 2,036 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $43.52M |
Open | High | Low | Value | Volume |
18.5¢ | 19.5¢ | 18.5¢ | $12.62K | 66.11K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 49388 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.5¢ | 63159 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 49388 | 0.190 |
4 | 117069 | 0.185 |
11 | 369640 | 0.180 |
7 | 163500 | 0.175 |
7 | 78000 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.195 | 63159 | 2 |
0.200 | 109923 | 3 |
0.205 | 15050 | 1 |
0.210 | 40000 | 1 |
0.215 | 104291 | 3 |
Last trade - 12.20pm 18/10/2024 (20 minute delay) ? |
Featured News
LGP
Record revenue of $10.2 million as European demand drives 40% quarterly growth, with $1 million in operating cash inflow and $0.5 million in cost savings forecast
EYE (ASX) Chart |